|
35
|
Hair Loss Treatment by JW0061-mediated Wnt modulation for “Growth in Hair length & follicular number” |
2022-11-21 |
|
34
|
JW Group Expands Global Territory of 'R&D Open Innovation' |
2022-07-13 |
|
33
|
JW Pharmaceutical’s Licensed Out ‘New Atopic Dermatitis Drug Candidate’ (JW1601) to enter Phase 2b dose-ranging clinical trial |
2021-12-15 |
|
32
|
JW Bioscience signs a non-exclusive license agreement with Immunovia (Sweden) for the patent ‘diagnostic biomarker of pancreatic cancer’ |
2021-09-13 |
|
31
|
JW Pharmaceutical Corporation signed a License Agreement for Fostamatinib with Kissei Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company. |
2021-06-28 |
|
30
|
JW Pharmaceutical announces the completion of the U.S. launch for the Ertapenem, the latest generation of Carbapenem antibiotic, for the first time in Korea. |
2021-06-09 |
|
29
|
JW Pharmaceutical presents the results from nonclinical studies of JW-2286 under development as the next-generation targeted anti-cancer at the AACR Annual Meeting 2021. |
2021-03-29 |
|
28
|
JW Pharmaceutical, Announce Successful Completion of a Phase 2b Clinical Trial of the Anti-gout Drug URC102 “JW opts for global out-licensing activities” |
2021-03-18 |
|
27
|
JW Pharmaceutical, Participates in 2021 JP Morgan Healthcare Conference |
2021-01-04 |
|
26
|
JW Pharmaceutical secures the rights to own and use the animal test results of ‘CWP291’ on COVID-19 from Korea Research Institute of Bioscience and Biotechnology (KRIBB) |
2021-01-04 |